Business Daily Media

Men's Weekly

.

Eisai Transfers Rights to Receive Royalties Outside of Japan for EZH2 Inhibitor Tazemetostat to Royalty Pharma

  • Written by ACN Newswire - Press Releases

image

TOKYO, Nov 5, 2019 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has entered into an agreement to transfer the rights to receive royalties on the sales outside of Japan for an investigational anti-cancer agent tazemetostat (generic name) to Royalty Pharma.

Tazemetostat is a first-in-class, oral EZH2 inhibitor discovered by Epizyme,...

Deputy partners with SuperAPI to streamline employee onboarding and help get shift-based industries ready for PayDay Super

Deputy, the global people platform for shift-based work, has announced a new partnership with SuperAPI, marking a major enhancement to its HR pro...

KuCoin invests in Australian sponsorships of the ACC, plus a major campaign with golf icon Adam Scott

KuCoin, a leading global crypto platform built on trust, announced the appointment of James Pinch as the Australian Managing Director, the establish...

Australian companies pitching to the world’s wealthiest investors

#CapTech 2025 to bring world investors to Australia’s doorstep  One of Australia’s leading business and capital events is bringing together inves...

Small business backlash builds as RBA’s surcharge ban risks fuelling inflation

Australia’s small business sector has launched a fierce campaign against the Reserve Bank of Australia’s (RBA) proposed ban on debit and credit card...

Australia’s Young Entrepreneurs Redefining Success Through Legacy and Community Impact

A new generation of young Australian small business owners is redefining success, driven by a desire to create a lasting legacy through the positi...

Lessons in AI: How LoanOptions.ai Shows What Smart Adoption Really Looks Like

In a world where many small businesses are still trying to work out how to actually use AI (not just talk about it), Australian fintech LoanOption...